WO2020055192A3 - Procédé de préparation d'un dérivé de quinoléine-5,8-dione qui est un inhibiteur de la tgase 2 - Google Patents

Procédé de préparation d'un dérivé de quinoléine-5,8-dione qui est un inhibiteur de la tgase 2 Download PDF

Info

Publication number
WO2020055192A3
WO2020055192A3 PCT/KR2019/011876 KR2019011876W WO2020055192A3 WO 2020055192 A3 WO2020055192 A3 WO 2020055192A3 KR 2019011876 W KR2019011876 W KR 2019011876W WO 2020055192 A3 WO2020055192 A3 WO 2020055192A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgase
quinoline
preparation
dione derivative
same
Prior art date
Application number
PCT/KR2019/011876
Other languages
English (en)
Korean (ko)
Other versions
WO2020055192A2 (fr
Inventor
송민수
임춘영
박가영
고은비
강지희
우서연
김숭현
황희종
이은혜
Original Assignee
재단법인 대구경북첨단의료산업진흥재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 대구경북첨단의료산업진흥재단 filed Critical 재단법인 대구경북첨단의료산업진흥재단
Publication of WO2020055192A2 publication Critical patent/WO2020055192A2/fr
Publication of WO2020055192A3 publication Critical patent/WO2020055192A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un dérivé de quinoléine-5,8-dione représenté par la formule chimique I, un stéréoisomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci. Un composé représenté par la formule chimique I de la présente invention présente un effet inhibiteur de la TGase 2, et une composition pharmaceutique le comprenant peut être utilisée utilement dans la prévention ou le traitement de troubles ou de maladies qui sont médiés par la TGase 2 ou réagissent à l'inhibition de la TGase 2.
PCT/KR2019/011876 2018-09-13 2019-09-11 Procédé de préparation d'un dérivé de quinoléine-5,8-dione qui est un inhibiteur de la tgase 2 WO2020055192A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0109841 2018-09-13
KR1020180109841A KR102377102B1 (ko) 2018-09-13 2018-09-13 TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체의 제조 방법

Publications (2)

Publication Number Publication Date
WO2020055192A2 WO2020055192A2 (fr) 2020-03-19
WO2020055192A3 true WO2020055192A3 (fr) 2020-05-07

Family

ID=69778055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/011876 WO2020055192A2 (fr) 2018-09-13 2019-09-11 Procédé de préparation d'un dérivé de quinoléine-5,8-dione qui est un inhibiteur de la tgase 2

Country Status (2)

Country Link
KR (1) KR102377102B1 (fr)
WO (1) WO2020055192A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010114122A (ko) * 2000-06-21 2001-12-29 권오령 신규 퀴놀린디온 유도체, 이의 제조방법 및 이를 포함하는약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728162B2 (en) 2004-11-02 2010-06-01 Daihachi Chemical Industry Co., Ltd. Process for preparing phosphorus compounds having phosphate-phosphonate bond
KR20090018388A (ko) 2007-08-17 2009-02-20 주식회사 대우아이에스 주차 안내 시스템 및 그 방법
KR101470115B1 (ko) 2013-01-09 2014-12-05 동국대학교 산학협력단 2-(페닐에티닐)티에노[3,4-b]피라진 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010114122A (ko) * 2000-06-21 2001-12-29 권오령 신규 퀴놀린디온 유도체, 이의 제조방법 및 이를 포함하는약학적 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONOHOE, T. J.: "Total Synthesis of ((±)-Streptonigr in: De Novo Construction of a Pentasubstituted Pyridine using Ring-Closing Metathesis", J. AM. CHEM. SOC., 2011, pages 16418 - 16421, XP055702871 *
DONOHOE, T. J.: "Total Synthesis of the Antitumor Antibiotic ((+)-Streptonigrin: First and Second Generation Routes for de Novo Pyridine Formation using Ring-Closing Metathesis", J. ORG. CHEM., 2013, pages 12338 - 12350, XP055702868 *
GODARD, A.: "New synthesis of the Streptonigrin Quinoline-5,8-quinone Moiety and Aromatic Cross-Coupling", SYNLETT, 1994, pages 235 - 236, XP055702875 *
KITAHARA, Y. O: "Synthesis of 5,8- and 5,6-Quinolinediones Using Oxidative Demethylation with Cerium(IV) Ammonium nitrate", CHEM. PHARM. BULL., 1997, pages 1697 - 1701 *

Also Published As

Publication number Publication date
WO2020055192A2 (fr) 2020-03-19
KR102377102B1 (ko) 2022-03-21
KR20200030970A (ko) 2020-03-23

Similar Documents

Publication Publication Date Title
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2021004431A (es) Procesos novedosos.
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
WO2008086014A3 (fr) Dérivés de bis-aryl amide et procédés d'utilisation
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
WO2017053868A8 (fr) Dérivés d'acide oléanolique modifié en c4 pour l'inhibition de l'il-17 et d'autres utilisations
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
WO2019226213A3 (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
WO2019224790A3 (fr) Promédicaments de fulvestrant
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
WO2017034242A3 (fr) Nouveau dérivé de catéchol et composition pharmaceutique le comprenant
EP3643302A4 (fr) Composition comprenant un dérivé de sesquiterpène en tant que principe actif pour la prévention ou le traitement de maladies musculaires
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
EP3949963A4 (fr) Nouveau composé et composition pour la prévention ou le traitement de maladies respiratoires comprenant celui-ci comme principe actif
WO2020055192A3 (fr) Procédé de préparation d'un dérivé de quinoléine-5,8-dione qui est un inhibiteur de la tgase 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19860405

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19860405

Country of ref document: EP

Kind code of ref document: A2